AI Engines For more Details: Perplexity Kagi Labs You
Antipsychotic Effects: Mesoridazine besylate exerts its therapeutic effects primarily by blocking dopamine receptors in the brain. This antagonism of dopamine receptors helps alleviate symptoms of psychosis, including hallucinations, delusions, and thought disturbances, which are characteristic features of schizophrenia and other psychotic disorders.
Treatment of Schizophrenia: Mesoridazine besylate is indicated for the treatment of schizophrenia, a chronic mental disorder characterized by distortions in thinking, perception, emotions, and behavior. It helps stabilize mood, reduce the severity of psychotic symptoms, and improve overall functioning in individuals with schizophrenia.
Management of Other Psychotic Disorders: In addition to schizophrenia, mesoridazine besylate may also be used in the management of other psychotic disorders, such as schizoaffective disorder, psychotic depression, and bipolar disorder with psychotic features. It can help control symptoms of psychosis and prevent relapse of acute episodes.
Sedative and Calming Effects: Mesoridazine besylate possesses sedative properties, which can help calm agitated or anxious patients with psychotic disorders. It may aid in reducing agitation, aggression, and restlessness commonly observed in individuals experiencing acute psychotic episodes.
Control of Behavioral Disturbances: Mesoridazine besylate may be used to manage behavioral disturbances associated with dementia, particularly in elderly patients. It can help alleviate agitation, aggression, and psychotic symptoms in individuals with dementia-related psychosis.
Side Effects: Like other antipsychotic medications, mesoridazine besylate is associated with a range of side effects, including sedation, drowsiness, dizziness, blurred vision, dry mouth, constipation, urinary retention, and orthostatic hypotension (drop in blood pressure upon standing). It may also cause extrapyramidal symptoms (EPS), such as parkinsonism, dystonia, akathisia, and tardive dyskinesia.
Cardiovascular Effects: Mesoridazine besylate has been associated with QT interval prolongation, which can predispose patients to potentially life-threatening ventricular arrhythmias, including torsades de pointes. Therefore, it should be used with caution in patients with a history of cardiac arrhythmias, heart failure, or electrolyte imbalances.
Monitoring: Patients taking mesoridazine besylate require regular monitoring for adverse effects, including cardiovascular effects, extrapyramidal symptoms, and changes in mental status. Electrocardiograms (ECGs) may be necessary to assess QT interval prolongation, especially in patients at higher risk.
Black Box Warning: Mesoridazine besylate carries a black box warning regarding the increased risk of mortality in elderly patients with dementia-related psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to those receiving placebo.
Contraindications: Mesoridazine besylate is contraindicated in patients with a known hypersensitivity to phenothiazines or any component of the medication. It should not be used in patients with a history of QT prolongation, ventricular arrhythmias, or other significant cardiac abnormalities.
Drug Interactions: Mesoridazine besylate may interact with other medications, including other antipsychotics, central nervous system depressants, anticholinergic agents, and medications that prolong the QT interval. Concurrent use of these medications may increase the risk of adverse effects or alter the therapeutic response.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 4 | 0.3 | 12.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 1.7 | 0.65 |
| Allergies | 5 | 2.1 | 1.38 |
| Allergy to milk products | 1.2 | 1.6 | -0.33 |
| Alopecia (Hair Loss) | 1.4 | 1.4 | |
| Alzheimer's disease | 5.2 | 5.7 | -0.1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 0.4 | 4.75 |
| Ankylosing spondylitis | 4.1 | 0.3 | 12.67 |
| Anorexia Nervosa | 1.3 | 2.6 | -1 |
| Antiphospholipid syndrome (APS) | 1.3 | 0.3 | 3.33 |
| Asthma | 4.6 | 2.2 | 1.09 |
| Atherosclerosis | 1.9 | 1.9 | 0 |
| Atrial fibrillation | 3.2 | 3 | 0.07 |
| Autism | 7.5 | 8 | -0.07 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1 | 1 | |
| Bipolar Disorder | 2.1 | 1.1 | 0.91 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.6 | 2 | -2.33 |
| Carcinoma | 3.8 | 2.3 | 0.65 |
| Celiac Disease | 2.7 | 2.7 | 0 |
| Cerebral Palsy | 1.4 | 1 | 0.4 |
| Chronic Fatigue Syndrome | 4.2 | 5.7 | -0.36 |
| Chronic Kidney Disease | 3.4 | 1.7 | 1 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.1 | -0.1 |
| Chronic Urticaria (Hives) | 1.8 | 1.2 | 0.5 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 1 | 0.7 |
| Cognitive Function | 3.2 | 1.6 | 1 |
| Colorectal Cancer | 5 | 2.6 | 0.92 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.9 | 2.7 | -0.42 |
| COVID-19 | 9.7 | 9.7 | 0 |
| Crohn's Disease | 7.4 | 4 | 0.85 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1 | 1.8 | -0.8 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 2.3 | 1.1 | 1.09 |
| Denture Wearers Oral Shifts | 0.5 | 0.5 | |
| Depression | 9.3 | 6.7 | 0.39 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.4 | 1.9 | -0.36 |
| Endometriosis | 3 | 1.5 | 1 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 3.3 | 1.7 | 0.94 |
| erectile dysfunction | 1.5 | 0.3 | 4 |
| Fibromyalgia | 3.5 | 1.9 | 0.84 |
| Functional constipation / chronic idiopathic constipation | 4.7 | 3.6 | 0.31 |
| gallstone disease (gsd) | 3.2 | 0.8 | 3 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 0.8 | 0.88 |
| Generalized anxiety disorder | 2 | 1.2 | 0.67 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.2 | 0.2 | 5 |
| Graves' disease | 1.6 | 2.7 | -0.69 |
| Gulf War Syndrome | 0.6 | 1.5 | -1.5 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.7 | 0.9 | 2 |
| Heart Failure | 2.3 | 1.6 | 0.44 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1.5 | 0.3 | 4 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.9 | |
| hyperglycemia | 1.2 | 1.1 | 0.09 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.5 | 4.5 | -0.29 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 3.2 | 0.8 | 3 |
| IgA nephropathy (IgAN) | 1.3 | 3.9 | -2 |
| Inflammatory Bowel Disease | 7.2 | 7 | 0.03 |
| Insomnia | 1.6 | 1.8 | -0.13 |
| Intelligence | 1.5 | 0.6 | 1.5 |
| Intracranial aneurysms | 0.9 | 0.3 | 2 |
| Irritable Bowel Syndrome | 6.2 | 4.4 | 0.41 |
| ischemic stroke | 2.2 | 1.7 | 0.29 |
| Liver Cirrhosis | 6.6 | 3.2 | 1.06 |
| Long COVID | 5.9 | 5.7 | 0.04 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 1.5 | 0.7 | 1.14 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.3 | 2 |
| ME/CFS with IBS | 0.7 | 1.6 | -1.29 |
| ME/CFS without IBS | 1.4 | 2.1 | -0.5 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.5 | 0.5 | 2 |
| Metabolic Syndrome | 6.8 | 7 | -0.03 |
| Mood Disorders | 8.3 | 5.8 | 0.43 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 5.4 | 5.2 | 0.04 |
| Multiple system atrophy (MSA) | 0.7 | 0.4 | 0.75 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.8 | -8.33 |
| Neuropathy (all types) | 0.7 | 2.2 | -2.14 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.2 | 3.3 | 0.58 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 8.3 | 5.2 | 0.6 |
| obsessive-compulsive disorder | 5.3 | 2.7 | 0.96 |
| Osteoarthritis | 2.5 | 0.9 | 1.78 |
| Osteoporosis | 2.2 | 1.3 | 0.69 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 5.9 | 5.7 | 0.04 |
| Polycystic ovary syndrome | 5.5 | 2.3 | 1.39 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.4 | -0.17 |
| Primary sclerosing cholangitis | 1.8 | 1.7 | 0.06 |
| Psoriasis | 3.2 | 2.8 | 0.14 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.7 | 4.1 | 0.39 |
| Rosacea | 0.3 | 0.7 | -1.33 |
| Schizophrenia | 4.9 | 2.2 | 1.23 |
| scoliosis | 0.4 | 0.3 | 0.33 |
| Sjögren syndrome | 2.8 | 3.1 | -0.11 |
| Sleep Apnea | 1 | 1.3 | -0.3 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.1 | 14 |
| Stress / posttraumatic stress disorder | 2.7 | 2.4 | 0.13 |
| Systemic Lupus Erythematosus | 3.7 | 1.3 | 1.85 |
| Tic Disorder | 1.2 | 1.7 | -0.42 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3.9 | 3.2 | 0.22 |
| Type 2 Diabetes | 7.8 | 6.7 | 0.16 |
| Ulcerative colitis | 5.5 | 6.5 | -0.18 |
| Unhealthy Ageing | 3.5 | 2.2 | 0.59 |
| Vitiligo | 1.9 | 0.9 | 1.11 |
